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ABSTRACT  52 
 53 
Background: Bacille Calmette-Guérin (BCG) vaccine is protective in children but its 54 
efficacy wanes with age. Consequently, determining if BCG revaccination augments 55 
anti-TB immunity in young adults in TB endemic regions is vital. 56 
Methods: 200 healthy adults, BCG vaccinated at birth were tested for their IGRA 57 
status. Of these, 28 IGRA+ and 30 IGRA- were BCG revaccinated and 24 IGRA+ and 58 
23 IGRA- subjects served as unvaccinated controls. T and innate cell responses to 59 
mycobacterial antigens were analysed by 14-colour flow cytometry over 34 weeks. 60 
Results: IFN-γ and/or IL-2 Ag85A and BCG-specific CD4+ and CD8+ T-cell 61 
responses were boosted by revacciantion at 4 and 34 weeks respectively and were 62 
>2-fold higher in IGRA+ compared to IGRA- vaccinees. Polyfunctional Ag85A, BCG 63 
and Mtb latency Ag (LTAg)-specific CD4+ T-cells expressing up to 8 cytokines were 64 
also significantly enhanced in both IGRA+ and IGRA- vaccinees relative to 65 
unvaccinated controls, most markedly in IGRA+ vaccinees. A focussed analysis of 66 
Th17 responses revealed expansion of Ag85A, BCG and LTAg-specific total IL-67 
17A+IL-17F+IL-22+ and IL-10+ CD4+ T-cell effectors in both IGRA+ and IGRA- 68 
subjects. Also, innate IFN-γ+ NK//NKT responses were higher in both IGRA+ and 69 
IGRA- vaccinees compared to controls. This is the first evidence that BCG 70 
revaccination significantly boosts anti-mycobacterial Th1/Th17 responses in IGRA+ 71 
and IGRA- subjects.    72 
Summary: These data show that BCG revaccination is immunogenic in IGRA- and 73 
IGRA+ subjects implying that Mtb pre-infection in IGRA+ subjects does not impact 74 
immunogenicity. This has implications for public health and vaccine development 75 
strategies.  76 
Funding: This work was funded principally by DBT-NIH (BT/MB/Indo-77 
US/HIPC/2013). 78 
INTRODUCTION 79 
Tuberculosis (TB) is the leading cause of death from a single infectious agent, 80 
Mycobacterium tuberculosis (Mtb). An estimated 10.4 million new TB cases occurred 81 
in 2017 (1). Almost a quarter of the world’s population in Asia and Africa is estimated 82 
to have latent Mtb infection (1, 2). These individuals generally develop active TB 83 
within five years of initial infection, while approximately 5-10% of those infected are 84 
at a higher risk of progressing towards disease during their lifetimes (3). BCG, a live 85 
attenuated strain of Mycobacterium bovis, first introduced in 1921, is the only 86 
clinically approved TB vaccine (4). Although BCG administered at birth significantly 87 
reduces the incidence of severe miliary and meningeal TB in infants and children, it 88 
is less effective against pulmonary TB in adults, the most common form of TB 89 
disease and the major source of transmission worldwide (5-8). Meta-analysis of 14 90 
prospective BCG efficacy studies involving 3855 participants revealed an estimated 91 
protective efficacy of 19% against Mtb infection based on interferon gamma (IFN-γ) 92 
release assay (IGRA) positivity and 58% against TB disease (9). Clearly, a more 93 
effective TB vaccine strategy is needed worldwide, and efforts to understand 94 
protective immunity against Mtb infection are a major global research priority. Here, 95 
we present a study designed to investigate the effects of BCG revaccination in 96 
boosting Mtb immunity in South Indian young adults, who are highly vulnerable to TB 97 
disease as their immunity to Mtb is likely waning since vaccination at birth.  98 
 99 
Many factors can account for the variable efficacy of BCG in different countries, but a 100 
consistent theme is that efficacy is suboptimal and protection wanes as children 101 
reach adolescence. Thus, the protective efficacy of BCG administered at birth rarely 102 
persists beyond 15-20 years in TB endemic regions; is highly variable in adults (6, 8) 103 
and differs considerably with geographical location and prior sensitization to Mtb or 104 
even other environmental and non-tuberculous mycobacteria (NTM) (10-12). 105 
Evidence from other studies shows that BCG and NTM responses can influence 106 
each other. BCG vaccination can offer protection against NTM infection in children 107 
(13, 14). BCG administration and M. tuberculosis infection in mice and human 108 
induces NTM cross-reactive T-cells (15). A 15-year follow-up of a randomized 109 
controlled BCG trial in South India, average protection was 32% (95% CI: 3–52%) 110 
among people who were initially non-responsive to NTMs detected by a Tuberculin 111 
Skin Test (TST); by contrast, no significant protection was observed in vaccine 112 
recipients previously exposed to NTMs (16). On the other hand, there is also 113 
evidence to suggest that prior exposure to NTM can affect BCG vaccine efficacy and 114 
the results of PPD skin test (17). Some have postulated that the lack of sustained 115 
protection after BCG vaccination may relate to the failure to establish a long-term 116 
central memory response (18). Furthermore, a reduced protective effect of BCG may 117 
occur with co-infections, especially HIV-1 infection (6, 7, 19), a known major 118 
predisposing factor for TB incidence (20-22).   119 
 120 
Recent efforts have focused on developing improved vaccines to prevent Mtb 121 
infection, since such a vaccine could have a high population-level impact for TB 122 
control and tailored pre-existing immunity may be more effective during acute 123 
infection than after persistent chronic infection (23). Current approaches under 124 
evaluation in animal models and some in humans include: 1) recombinant live 125 
attenuated vaccines with improved efficacy over BCG, such as new mycobacterial 126 
vaccine designs, as well as CMV and chimp adenovirus vectors containing Mtb 127 
antigens, 2) boosting BCG with homologous BCG or subunit vaccines such as 128 
H4:IC31 and 3) delivery of TB vaccines by aerosolization rather than systemically 129 
(24-27). Revaccination with BCG in adolescence has been in routine practice in 130 
many countries throughout the world with variable benefit (28). Moreover, BCG 131 
revaccination in diverse age groups and regional TB incidence has yielded 132 
inconsistent levels of protection against TB disease (29-42).   133 
 134 
There is renewed interest in BCG revaccination of young adults, especially in 135 
countries with high TB burden (43-44), based on recent positive results from the 136 
Aeras C-040-404 randomized, placebo-controlled, prevention of infection TB vaccine 137 
study (45). This study was conducted in the Western Cape Province of South Africa 138 
among 990 HIV-negative, healthy adolescents BCG vaccinated at birth. Mtb-139 
uninfected subjects were randomized to receive either placebo, H4:IC31, or BCG 140 
revaccination. When compared to placebo, neither vaccine achieved statistical 141 
significance in preventing an initial QFT-GIT conversion. However, analysis of the 142 
secondary efficacy endpoint indicated that BCG revaccination reduced sustained Mtb 143 
infection in young adolescents by 45.4% and H4:IC31 reduced sustained Mtb 144 
infection by 30.5% (45). A follow up efficacy trial is planned to confirm these findings 145 
and to examine potential biomarkers of protective immunity.   146 
 147 
Few studies have reported detailed analysis of the immune profile alterations 148 
following BCG revaccination in humans, and among these, populations evaluated 149 
have varied by age group and status of Mtb infection. Revaccination of infants 150 
induced a significant increase in IFN-γ and IL-10 concentrations in three-day whole 151 
blood culture supernatants to PPD stimulation (46, 47). Others have reported that 152 
BCG revaccination of TST-positive subjects on INH treatment elicited long-lived 153 
memory NK and NKT-like cells besides transiently boosting BCG-specific Th1 154 
cytokines in CD4+, CD8+ and T-cell receptor (TCR) γδ cells using an intracellular 155 
cytokine staining (ICS) assay (48). In an extensive immune profiling study, we 156 
recently reported a key distinguishing feature of subjects with latent TB infection (not 157 
on INH treatment) to be the presence of circulating Mtb-specific central memory 158 
polyfunctional CD4+ T-cells, that co-expressed IL-17A/IL-17F/IL-22 with IL-10; this 159 
specific Th17 subset was either lacking or significantly reduced in the 160 
bronchoalveolar lavage of subjects with pulmonary disease or in the blood of 161 
subjects with extrapulmonary TB (49). By contrast, subjects with either pulmonary or 162 
extrapulmonary TB had expanded frequencies of pro-inflammatory Th17 cells that 163 
co-expressed IL-17A/IL-17F/IL-22 with IFN-γ (49). These data from our laboratory on 164 
a potential role for Mtb-specific IL-17+ and IL-10+ cells in anti-TB immunity has been 165 
extended in a recent publication using a macaque in vivo TB challenge model, which 166 
highlighted the key cells associated with protection against live bacterial challenge 167 
following BCG vaccination to be Mtb-specific CD4+ T-cells that expressed IL-17 and 168 
other IL-10 producing immune cells (50). Therefore, a major aim of our current study 169 
was to determine if BCG revaccination can boost circulating frequencies of Mtb-170 
specific Th17 CD4+ T-cells in both IGRA+ and IGRA- young adults, a highly 171 
vulnerable population, living in an HIV endemic area of South India.  172 
 173 
Detailed immune profiling of subjects following BCG revaccination, has not been 174 
reported from India. We present novel data to show that BCG revaccination of young 175 
adults in India can enhance a Mtb-specific CD4+ T-cell immune signature potentially 176 
associated with controlled TB infection. 177 
  178 
RESULTS 179 
Mtb antigen-specific CD4+ T-cells are preserved in young adults receiving BCG 180 
at birth  181 
Two hundred volunteers who were HIV-ve, TB-ve, Hep B Ab-ve and BCG vaccinated 182 
at birth, living in Madanapalle, India, were recruited (Figure 1A). Volunteers were 183 
divided into four groups based on both screening for IGRA status and then 184 
randomisation to receive BCG revaccination at T0 (Figure 1, A and B). All volunteers 185 
subsequently received three doses of hepatitis B virus surface antigen vaccine at 186 
weeks 4 (T2), 10 (T4) and 30 (Figure 1, A and B) (see materials and methods). The 187 
median age of the study population was 20 years (range, 18-28 years) and 58.75% 188 
were female (Table 1, Supplemental File 1). The approximate male:female ratio in 189 
different clinical groups was: Groups 1 43:57, Group 2: 39:61, Group 3 - 61:39 and 190 
Group 4 -22:78. The median IGRA levels in Groups 1 and 3 were similar (median for 191 
Group 1 - 3.6; for Group 3 – 2; range 0.46-10). The median IGRA values for IGRA- 192 
subjects (Groups 2 and 4) were ≤ 0.1 (range 0 – 0.3) (Table 1, Supplemental File 1).   193 
Multiparameter flow cytometry was performed on whole blood to assess the 194 
presence of T-cells recognizing Mtb antigens prior to revaccination (Ag85A, TB10.4, 195 
BCG), which would reflect baseline responses maintained either by BCG vaccination 196 
at birth and/or prior exposure to cross-reactive NTM. Representative whole blood 197 
flow cytometry plots depicting the stepwise gating strategy to identify functional 198 
subsets are shown in Supplemental Figure 1. Cross-sectional analysis of baseline 199 
CD4+ T-cell responses measured as frequencies of IFN-γ and/or IL-2  expressing 200 
cells in IGRA+ vs. IGRA- donors revealed that recall responses to Mtb antigens 201 
TB10.4 and Ag85A, and BCG (used as antigen for in vitro stimulation) were well 202 
preserved in both groups, with high basal responses particularly to BCG antigens 203 
(Figure 2). As expected, IGRA+ subjects had significantly higher baseline CD4+ T-cell 204 
responses to epitopes in BCG and TB10.4 compared to IGRA- subjects recruited to 205 
the study (Figure 2). Baseline antigen-specific CD8+ T-cell frequencies were 206 
generally lower than the CD4+ T-cell frequencies, and notably the BCG-specific CD8+ 207 
T-cell responses were greater than the responses to Ag85A and TB10.4 (Figure 2). 208 
No significant differences were observed between the median IGRA+ and IGRA- 209 
CD8+ T-cell recall responses at baseline (Figure 2). These data provide clear 210 
evidence of baseline CD4+ T-cell responses to Ag85A and TB10.4 peptides in IGRA+ 211 
and IGRA- subjects and to epitopes presented by BCG with the magnitude of this 212 
baseline response varying significantly between donors in a group. These data 213 
indicate preservation of memory CD4+ T-cells recognizing BCG and Mtb antigens in 214 
both IGRA+ and IGRA- volunteers recruited to this study, reflecting responses either 215 
induced by BCG vaccination at birth or by exposure to environmental cross-reactive 216 
mycobacteria. 217 
Longitudinal analysis reveals BCG revaccination significantly enhances 218 
Ag85A- and BCG-specific CD4+ and CD8+ T-cell responses 219 
We next determined whether BCG revaccination could increase Mtb-specific CD4+ 220 
and CD8+ T-cell responses in whole blood of IGRA+ and IGRA- young adults above 221 
baseline responses in a longitudinal study with representative gating shown in 222 
Supplemental Figure 1.  We demonstrate significant enhancement post vaccination, 223 
in frequencies of Ag85A (Figure 3A) and BCG (Figure 3E) specific CD4+ T-cells 224 
expressing IFN-γ and/or IL-2. The peak median fold increase over baseline was 2.3 225 
fold for Ag85A (at T2) and 5.7-fold for BCG (at T5) in Group 1 IGRA+ subjects (Figure 226 
3, B and F). Similar enhancement was also noted for Ag85A (Figure 3B) but not BCG 227 
(Figure 3F) specific CD4+ T-cell frequencies in Group 2 IGRA- vaccinees, possibly 228 
due to baseline responses in the IGRA- subjects being lower than the IGRA+ subjects 229 
(see Figure 2). By comparison, these responses did not significantly differ over time 230 
in non-vaccinated Group 3 and 4 control subjects (Figure 3, B and F). Evidence of an 231 
enhanced CD4+ T-cell response in vaccinees was maintained in a cross-sectional 232 
analysis of this data, despite significant intra-group variation. Thus, higher Ag85A 233 
(Figure 3C) and BCG (Figure 3G) specific IFN-γ+ and/or IL-2+ CD4+ T-cell 234 
frequencies were noted in Group 1 compared to Group 3 subjects, with Ag85A 235 
responses peaking at T2 (Figure 3C) and BCG responses at T5 (Figure 3G).   236 
BCG revaccination substantially enhanced Ag85A (Figure 4A) and BCG (Figure 4E) 237 
specific IFN-γ+ and/or IL-2+ CD8+ T-cell frequencies. In Group 1 IGRA+ vaccinees, 238 
median CD8+ T-cell responses were enhanced above baseline (T0) by 15.1 fold for 239 
Ag85A at T2 (Figure 4B) and 14.4 fold for BCG at T5 (Figure 4F). However, in Group 240 
2 IGRA- vaccinees, only Ag85A but not BCG specific CD8+ T-cell responses were 241 
boosted (Figure 4, B and F). This enhancement was not observed in unvaccinated 242 
Group 3 and Group 4 control subjects (Figure 4, B and F). Cross-sectional analysis 243 
of this data showed higher CD8+ T-cell responses to Ag85A at T2 but not to BCG in 244 
Group 1 ‘vs’ Group 3 (Figure 4, C and G).  245 
The memory composition of vaccine-induced T-cells was analysed using CD45RA 246 
and CD27 markers. The baseline IFN-γ and/or IL-2 expressing CD4+ T-cells specific 247 
for Ag85A and BCG comprised a mixture of naïve (N), central memory (CM), effector 248 
memory (EM) and terminally differentiated effector memory expressing CD45RA 249 
(TD) cells (Figure 3, D and H). BCG revaccination expanded Ag85A-specific CD4+ 250 
EM T-cells in Group 1 IGRA+ subjects but not Group 2 IGRA- subjects at T2 (4 251 
weeks) relative to T0 (Figure 3D); in contrast, there was no significant change in 252 
memory subset composition in BCG-specific cells (Figure 3H). In addition, there were 253 
no significant longitudinal changes in subset composition in the CD8+ T-cell 254 
compartment (Figure 4, D and H).  255 
The Mtb-specific vaccine induced T-cell response was probed further by analysing 256 
CD4+ and CD8+ T-cell frequencies to another immunodominant antigen, namely TB 257 
10.4, which is a part of the well-recognised esat-6 gene family (51) using a pool of 258 
overlapping peptides. In contrast to Ag85A and BCG-specific responses, TB10.4 259 
responses were not significantly induced in both IGRA+ and IGRA- vaccinees (see 260 
Supplemental Figure 2), demonstrating selectivity in the enhancement of Mtb-specific 261 
responses by revaccination.  262 
Finally, a comparison of immunostaining of matched whole blood and PBMC 263 
samples in ten subjects showed significant correlation (Figure 5A). Representative 264 
PBMC flow cytometry plots depicting gating strategy is shown in Supplemental 265 
Figure 3. Ag85A and BCG-specific IFN-γ+ and/or IL-2+ CD4+ T-cell frequencies show 266 
significantly higher frequencies over baseline T0 responses with Ag85A at T2 and 267 
BCG at T5 in Group 1 IGRA+ in whole blood and PBMC (Figure 5B). Taken together, 268 
these data provide strong evidence of the capacity of BCG revaccination to 269 
significantly boost IFN-γ+ and/or IL-2+ CD4+ and CD8+ T-cell responses in IGRA+ 270 
subjects over and above the inherently variable baseline responses. Also, the data 271 
shows that BCG revaccination induced a transient increase of Ag85A responses in 272 
Group 2 IGRA- participants, but not to BCG. 273 
Longitudinal analysis reveals BCG revaccination to significantly enhance 274 
Ag85A- and BCG-specific CD4+ and CD8+ T-cell polyfunctional response in 275 
both IGRA+ and IGRA- subjects 276 
To examine co-expression of effector cytokines, we used COMPASS, as in our 277 
previous study (49) to enumerate antigen-specific polyfunctional responses of total 278 
CD4+ and CD8+ T-cells, in whole blood samples by analysing all 64 possible 279 
combinations of IFN-γ, IL-2, TNF-α, IL-17A and MIP-1β. Polyfunctional responses to 280 
Ag85A and BCG stimulation were determined over time and summarized through the 281 
COMPASS polyfunctionality score (PFS) (Figure 6). Differences in PFS between 282 
groups were estimated through a linear model fit to the PFS for each antigen (see 283 
Methods). After multiple testing adjustments, significant increase in PFS scores 284 
compared to baseline were observed in Group 1 IGRA+ and Group 2 IGRA- CD4+ T-285 
cell responses to BCG epitopes at T5 and in Group 2 Ag85A-specific CD4+ T-cells at 286 
T2. Polyfunctional CD8+ T-cell responses were significantly enhanced over baseline 287 
in Group 1 in response to both Ag85A at T2 and BCG epitopes at T5, and in Group 2 288 
in response to Ag85A at T2. However, no increase in CD4+ and CD8+ T-cell PFS was 289 
noted in subjects from unvaccinated controls in Groups 3 (IGRA+) and 4 (IGRA-), 290 
relative to baseline responses at T0. The CD4+ T-cell polyfunctionality response to 291 
BCG was more prominent than the CD8+ T-cell response, whereas the Ag85A-292 
specific CD8+ polyfunctional response was the dominant one compared to its CD4+ 293 
response as reflected in the p-values between T0 ‘vs’ T2 for Ag85A and T0 ‘vs’ T5 294 
for BCG in both Group 1 and 2 (Figure 6).  295 
Heatmaps were constructed to identify the specific combinations of immune subsets 296 
that were expanded by BCG revaccination in Groups 1 and 2. Data from all subjects 297 
in the four clinical groups were analyzed for CD4+ (Figure 7, upper panel) and CD8+ 298 
(Figure 7, lower panel) polyfunctional T-cell responses at baseline and at T2 and T5 299 
post-BCG vaccination following Ag85A and BCG stimulation respectively. The 300 
Ag85A-specific CD4+ T-cell response was more marked in IGRA+ Group 1 vaccinees 301 
with enhanced expression of 1+ (IFN-γ, MIP-1β), 2+ (TNF-α/MIP-1β, IFN-γ/MIP-1β) 302 
and 3+ (IFN-γ/TNF-α/MIP-1β) subsets compared to baseline or Group 3 unvaccinated 303 
controls. The data also highlight the CD4+ T-cell responses induced by BCG antigens 304 
were more polyfunctional compared to those induced by Ag85A, with higher 305 
frequencies of 3+ and 4+ cells producing different combinations of IFN-γ, IL-2, IL-17, 306 
TNF-α and MIP-1β in addition to 1+, 2+ cells. Longitudinal analysis of polyfunctional 307 
BCG-specific CD4+ T-cells shows Group 1 and Group 2 vaccinees to have higher 308 
probabilities of the 4+ (IFN-γ/IL-2/TNF-α/MIP-1β), 3+ (IFN-γ/IL-2/TNF-α, IFN-γ/IL-309 
2/MIP-1β) and 2+ (IFN-γ/IL-2) subsets compared to baseline (Figure 7, upper panel). 310 
Among CD8+ T-cells, BCG revaccination induced a robust increase in 3+ subset 311 
expressing three cytokines (IFN-γ/TNF-α/MIP-1β), 2+ (combinations of IFN-γ, TNF-α, 312 
MIP-1β) and 1+ (IFN-γ, TNF-α, MIP-1β) cells in IGRA+ Group 1 and IGRA- Group 2 313 
subjects vs. unvaccinated controls (Group 3 and Group 4) in response to Ag85A 314 
stimulation. BCG specific CD8+ responses (1+ and 2+) were high for Group 1 and 2 315 
vaccinees compared to baseline (Figure 7, lower panel). 316 
The above whole blood data were extended using PBMC staining with a panel 317 
measuring eight effector cytokines (IFN-, IL-2, TNF-, MIP-1, IL-17A, IL-17F, IL-22 318 
and IL-10; Supplemental Table 1B). COMPASS analysis of PBMC data confirms the 319 
enhanced Ag85A and BCG CD4+ polyfunctional scores (PFS) noted in whole blood 320 
and extends the data to include latency antigens (Figure 8). A cross sectional 321 
analysis of whole blood data shows significantly higher Ag85A and BCG PFS scores 322 
in Group 1 ‘vs’ Group 3 (Figure 8A). At the PBMC level, these differences are 323 
confirmed (Figure 8B), but in addition, we note higher PFS scores to BCG but not 324 
Ag85A in Group 2 ‘vs’ Group 4 subjects. We further demonstrate through analysis of 325 
PBMC that Group 1 IGRA+ vaccinees had significantly higher LTAg PFS scores 326 
compared to unvaccinated controls (Figure 8B). These data collectively confirm that 327 
BCG revaccination has the potential to boost Mtb-specific polyfunctional CD4+ and 328 
CD8+ T-cells, in both IGRA+ and IGRA- young adults with the boosting effect being 329 
more consistent across all antigens tested in IGRA+ subjects.  330 
BCG revaccination enhances Mtb-specific Th17 responses 331 
Our previous studies highlight a key potential role of CD4+ Th17 cells in Mtb infection 332 
with functional differences noted between subjects with latent TB and TB disease 333 
(49). Thus, Mtb-latency antigen-specific IL-10+ regulatory Th17 cells expressing IL-334 
17A, IL-17F and IL-22 were significantly higher in subjects with latent TB compared 335 
to those with active TB disease. By contrast, subjects with TB disease had 336 
significantly higher numbers of Mtb-specific IL-17A or IL-17F or IL-22 cells that co-337 
expressed IFN-γ but not IL-10, indicating a shift to an Mtb-specific Th17 pro-338 
inflammatory CD4+ T-cells during disease, with this shift being best revealed by CD4+ 339 
T-cells specific for the DosR latency antigens, rather than the commonly studied 340 
secretory mycobacterial antigens (49). Therefore, we sought to determine if BCG 341 
revaccination could boost circulating frequencies of Mtb-specific IL17+ and IL-10+ 342 
total and double-positive Th17 cells in both IGRA+ and IGRA- vaccinees, comparing 343 
PBMC responses specific for Ag85A, BCG and latency antigens.  344 
First, we show in Figure 9 (upper panel), representative dot plots of CD4+ T-cells 345 
expressing Th17 cytokines at 34 weeks (T5) post-vaccination in BCG stimulated 346 
PBMCs from a Group 1 and Group 3 subject (see Supplemental Figure 4 for 347 
immunostaining of unstimulated control sample). Figure 9 (lower panel) summarises 348 
total frequencies of effector CD4+ T-cells that express IL-17A, IL-17F, IL-22, IFN-γ 349 
and IL-10 and highlights all these cytokine positive cells to be significantly higher in 350 
IGRA+ vaccinees (Group 1) compared to unvaccinated IGRA+ controls (Group 3) 351 
especially to Ag85A and BCG stimulation. LTAg responses were similar but not 352 
significantly different for IL-17A (Figure 9, lower panel). We also record significantly 353 
higher frequencies of total CD4+ T-cells expressing IL-17A, IL-17F, IL-22 and IL-10 in 354 
IGRA- Group 2 vaccinees compared to Group 4 unvaccinated IGRA- controls (Figure 355 
9, lower panel). These data provide strong evidence that BCG revaccination has the 356 
potential to boost Mtb-specific Th17 responses in both IGRA+ and IGRA- subjects.  357 
We next determined the frequencies of double-positive specific CD4+ T-cells that co-358 
expressed IL-17A or IL-17F or IL-22 with either IFN-γ (pro-inflammatory Th17) or IL-359 
10 (regulatory Th17), with representative gating data shown in Supplemental Figure 360 
5 and 6 highlighting these double positive cells to be a minor subset, confirmed by 361 
backgating to be viable cells. Figure 10 shows significantly higher frequencies of IL-362 
17F+IL-10+ cells specific for Ag85A and BCG in both Group 1 IGRA+ and Group 2 363 
IGRA- vaccinees relative to unvaccinated controls, with higher proportion of 364 
responders in Group 1 (50-80%) and Group 2 (20-40%) compared to unvaccinated 365 
Group 3 (10%) and 4 (10%), respectively. LTAg-specific IL-17F/IL-10 was also higher 366 
than unvaccinated controls, but only in Group 1 IGRA+ vaccinees. With the exception 367 
of Ag85A in Group 1 vaccinees, revaccination did not enhance Th17 proinflammatory 368 
cells that co-expressed IL-17A or IL-17F or IL-22 with IFN-γ (Figure 10). Thus, the 369 
extent to which specific cells were upregulated differed by antigen specificity and 370 
were evident in some but not all vaccinees. These data demonstrate that BCG 371 
revaccination has the potential to enhance a minor Mtb-specific anti-inflammatory, 372 
regulatory Th17 subset in both IGRA+ and IGRA- subjects.  373 
BCG revaccination-induces innate specific cells  374 
A previous study (48) had reported that BCG revaccination in adults transiently 375 
induces BCG-reactive γδ+, CD56+ NKT-like, CD56dim and CD56hi NK cells that 376 
express IFN-γ in IGRA+ subjects. We therefore evaluated whether BCG revaccination 377 
modulated the frequencies and function of innate lymphocyte populations. A 378 
representative example of the flow cytometric gating strategy to analyse these cells 379 
is shown in Supplemental Figure 7. Revaccination induced significant expansion of 380 
Ag85A reactive innate effectors (γδ, CD56br NK cells) above baseline T0 responses 381 
in both Group 1 IGRA+ and Group 2 IGRA- vaccinees and NKT-cells in Group 1 only 382 
but not Group 3 and 4 unvaccinated controls (Figure 11) with the boosting effect 383 
ranging from 2-10-fold depending on the innate effector subset and was more 384 
consistent (in terms of proportion of vaccinees responding) in Group 1 IGRA+ 385 
subjects. BCG reactive innate effectors (γδ, CD56dimNK, CD56br NK and NKT-cells) 386 
were significantly boosted at T5 (2-10-fold) above baseline T0 only in Group 1 IGRA+ 387 
and not in Group 2 IGRA- vaccinees. Interestingly, the pattern of induction of these 388 
innate subsets was similar to the induced adaptive response (Figure 3 and 4). Thus, 389 
IFN-γ+ innate lymphocytes induced by Ag85A re-stimulation peaked at T2 (4 weeks) 390 
post revaccination, whereas, those specific to BCG epitopes were observed later at 391 
T5 (34 weeks) post revaccination. These data highlight the potential of BCG to boost 392 
innate Mtb-reactive cells in both Group 1 and Group 2 IGRA+ and IGRA- subjects.  393 
 394 
  395 
Discussion  396 
We provide the first detailed evidence of the impact of BCG revaccination on Mtb-397 
specific T-cell immunity in young adults from a TB endemic region of India. Our work 398 
confirms and extends in particular the report of Suliman et al on immune stimulating 399 
effects of BCG revaccination of young adults with latent TB living in South Africa 400 
(48). Novel aspects of our work include: (i) detailed investigation of polyfunctional 401 
Mtb-specific T-cells including up to 256 immune subsets; (ii) focused analysis of Mtb-402 
specific pro-inflammatory as well as regulatory Th17 responses, the latter of which 403 
are highlighted to be of increasing importance in anti-TB immunity, based on our 404 
work and that of others (49, 50), and (iii) comparative longitudinal analysis of 405 
vaccine-induced responses in both IGRA+ ‘vs’ IGRA- subjects, in the absence of anti-406 
TB treatment.  407 
 408 
The strong evidence we provide that BCG revaccination can boost polyfunctional 409 
Th1/Th17 and innate effectors in  subjects living with latent TB in the absence of INH 410 
treatment distinguishes our study from that of the Suliman et al study (48), where 411 
TST+ subjects were randomised into two arms: one receiving BCG revaccination 412 
after INH and the other receiving BCG revaccination first and then INH. In the 413 
Suliman et al study (48), immune responses did not differ between these treatment 414 
groups implying pre-treatment with INH does not interfere with BCG revaccination 415 
potency. In this paper we asked a different question: whether BCG revaccination can 416 
boost anti-TB immunity in the absence of INH treatment altogether. The fact that we 417 
demonstrate this to be the case is important as current thinking proposes that 418 
underlying infection with Mtb or cross-reactive NTM responses (10-13, 17) can 419 
potentially blunt responses to BCG revaccination. Hence most BCG revaccination 420 
studies have focussed on subjects without Mtb infection (IGRA-) or latent TB subjects 421 
(IGRA+) after INH. IGRA+ individuals live with a considerably higher risk of 422 
succumbing to active TB (52). The results from our study show that Ag85A, BCG and 423 
LTAg-specific specific CD4+ and CD8+ T-cell responses are boosted to a greater 424 
extent in IGRA+ rather than IGRA- individuals. Thus, in India BCG revaccination 425 
might be more beneficial to the more susceptible IGRA+ population. This has 426 
implications for future BCG revaccination/other TB vaccination strategies.  427 
 428 
All the antigens tested in this study (Ag85A, TB10.4 and DosR regulon encoded 429 
latency antigens) are encoded by BCG (53-56). Our own and previous studies have 430 
shown that BCG vaccination does not lead to generation of potent immune 431 
responses against DosR encoded latency antigens (49, 55, 56). However, we show 432 
in this paper that DosR specific T-cell responses can be boosted by BCG 433 
revaccination of young Indian adults. Ag85A and TB10.4 are both vaccine candidates 434 
and have shown protection against M. tuberculosis infection in animal models (57-435 
60). In addition, Ag85A was found to be well tolerated in BCG vaccinated infants and 436 
significantly boosted Ag85A-specific Th1 and Th17 responses (61). H4:IC31, another 437 
candidate vaccine comprising Ag85B and TB10.4 was tested in adolescents and 438 
found to be immunogenic and capable of reducing the rate of sustained Quantiferon 439 
(QFT) conversion (45). DosR encoded latency antigens, which we and others show 440 
to distinguish subjects with latent and active TB individuals (49, 62) was also shown 441 
to have protective efficacy in NHP, most likely via induction of CD4+ as well as CD8+ 442 
T-cells. In this context, whether BCG revaccination of young IGRA+ adults can induce 443 
protective immunity and reversion of IGRA+ untreated subjects to an IGRA- state 444 
remains to be tested.  445 
 446 
The importance of probing adaptive T-cell responses to Mtb antigens is based on 447 
significant data from mouse knockout models demonstrating the dominant role of 448 
CD4+, and to a lesser extent CD8+ Mtb-specific T-cells in protection against Mtb 449 
infection following immunization with BCG (63, 64). While Suliman et al (48) reported 450 
peak responses at 3 weeks post revaccination, we report peak BCG responses to 451 
occur later, at 34 weeks post revaccination. This disparity may reflect differences in 452 
the BCG strains used. Further, the TST+ subjects recruited to the Suliman et al study 453 
(48) received INH whereas IGRA+ subjects recruited to our study remained treatment 454 
naive. We also show significantly enhanced Ag85A responses in both IGRA+ and 455 
IGRA- revaccinated subjects that transiently peaked at T2 (4 weeks) post 456 
revaccination, consistent with the observation that Ag85A responses following BCG 457 
vaccination in infants (61) and in murine models are transient based on low antigen 458 
load (65). Comparative analysis of the boosting effect in IGRA+ versus IGRA- 459 
subjects revealed a more marked effect in IGRA+ subjects, who had a higher 460 
baseline specific T-cell response; consequently, the more efficacious boosting effect 461 
of BCG revaccination may be due to expansion of pre-existing memory T-cells. 462 
Beyond analysis of T-cell responses and in keeping with the findings of Suliman et 463 
al., our study also shows that NK, NKT and γδ T-cell BCG-specific responses are 464 
boosted in IGRA+ vaccinees. These data provide strong evidence that BCG 465 
revaccination has the potential to boost both the innate and adaptive arms of the 466 
immune system in adults in the time frame of 9 months/34 weeks post vaccination.  467 
 468 
Beyond IFN-γ and/or IL-2 specific T-cell responses, we used the statistically robust 469 
COMPASS analysis to probe polyfunctional T-cell responses encompassing 8 470 
effectors representing a total of 256 immune subsets (66). Polyfunctional Mtb-471 
specific CD4+ T-cells simultaneously expressing IFN-γ, IL-2, and TNF-α in blood are 472 
implicated in anti-TB immunity (67, 68) and shown to be critical in modulating 473 
vaccine-mediated immunity in murine re-challenge studies (69-72). Further, we 474 
previously showed Mtb-specific polyfunctional cells expressing up to 4 cytokines to 475 
be associated with controlled latent infection, (49). Herein, we report that BCG 476 
revaccination significantly boosts circulating frequencies of CD4+ and CD8+ 477 
polyfunctional T-cells expressing up to 4 effectors (IFN-γ, IL-2, TNF-α, IL-17A) 478 
specific to Ag85A and BCG, in both IGRA+ and IGRA- subjects. In addition, we 479 
conducted a more focussed analysis of Th17 cells, which have emerged as potential 480 
correlates of protective immunity in human studies (see 49) and in vaccine-induced 481 
protection against TB (50, 73-76). Th17 subsets that express pro-inflammatory 482 
cytokines (IL-17A/IL-17F/IL-22 in combination with IFN-γ) are associated with 483 
pathogenesis of several chronic disease conditions; in contrast, subsets that express 484 
Th17 cytokines in combination with IL-10 can protect against disease pathology and 485 
therefore implicated to be protective in chronic conditions (77). In this manuscript, we 486 
demonstrate that BCG revaccination significantly boosted a minor population of anti-487 
inflammatory CD4+ T-cells specific for Ag85A, BCG and LTAg that co-expressed IL-488 
17F and IL-10 in a proportion of IGRA+ and IGRA- vaccinees, whilst the boosting 489 
effect of pro-inflammatory cells expressing IFN-γ and IL-17 was weaker and only 490 
noted to Ag85A stimulation. These data call for further studies to probe the potential 491 
efficacy of BCG revaccination in regulating Th17 responses.  492 
There is evidence for at least three potential mechanisms for the immunogenic 493 
function of BCG. First, BCG revaccination may expand pre-existing memory T-cells. 494 
Continuous T-cell stimulation by underlying infection is known to maintain a higher 495 
basal Mtb-specific adaptive T-cell response in IGRA+ compared to IGRA- subjects, 496 
and BCG revaccination may induce the proliferation of these pre-existing cells. 497 
Secondly, BCG may boost T-cell responses through immunomodulatory anti-498 
inflammatory effects, especially through IL-10 upregulation (78). This is consistent 499 
with our observation that BCG revaccination can induce total IL-10 Mtb-specific CD4+ 500 
T-cells and is supported by data on mucosal BCG vaccination in mice, which induces 501 
airway CD103−CD69+CD4+ memory T-cells, likely to be tissue resident memory 502 
(TRM) cells, that represent a heterogeneous population comprising of Foxp3+- or T-503 
bet+- T-cell subsets, producing IL-10 in addition to Th1 response (79). Thirdly, BCG 504 
may regulate innate immune cells in a pathogen specific manner and thereby provide 505 
resistance to secondary infections through “trained immunity” through potential 506 
epigenetic changes (80-82). Suliman et al reported that BCG-reactive CD3+CD56+ 507 
NKT-like cells as well as CD56hiCD16lo and CD56dimCD16+ NK cells to persist for up 508 
to 1 year post BCG revaccination, suggesting memory function akin to conventional 509 
T-cells (48). We too report an increase of CD3+CD56+ NKT and CD56br and CD56br 510 
NK cells in BCG revaccinated IGRA+ subjects in response to Ag85A and BCG 511 
stimulation at 4 and 34 weeks post revaccination, confirming a further mechanism of 512 
the beneficial effects of BCG revaccination through potential regulation of innate 513 
immunity. 514 
 515 
The importance of the immunostimulatory effects of BCG revaccination has to be 516 
placed in the broader context of immune components that may protect against Mtb 517 
infection. This has fundamental challenges because dominant immune responses 518 
elicited by vaccines in blood may not predict necessary effector responses in lung 519 
tissue following Mtb exposure by inhalation. Murine studies demonstrate that Mtb 520 
infects phagocytes with diverse phenotypes and that infected myeloid dendritic cells 521 
migrate from lungs to local lymph nodes early in infection, where T-cell activation can 522 
occur (83). Thus, a desirable vaccine might elicit innate immune activation of local 523 
myeloid cells that can kill the bacteria in the lung as well as T-cells that can rapidly 524 
enter the lung parenchyma, recognize infected cells and destroy them (84, 85). This 525 
calls for further studies on key immune innate and adaptive phenotypes post-526 
immunization including specific T-cells that are imprinted to traffic to lung tissue. Our 527 
data on the boosting effects of BCG in a TB endemic region of South India together 528 
with the reported efficacy of BCG revaccination in prevention of infection in South 529 
Africa (45) provide a rational basis for further mechanistic analysis of the 530 
immunostimulatory effects of BCG in divergent populations based on geography and 531 


















Study population 550 
A total of 200 young adults (age 18-28 years), mostly nursing college students from 551 
Madanapalle, South India, a TB endemic area, were prospectively recruited between 552 
January 2014 and December 2015 for the vaccination study primarily by college-wide 553 
informational seminars. All participants were confirmed as HIV-1 seronegative and 554 
BCG vaccinated at birth and had a visible BCG scar. Relevant clinical information of 555 
study participants was documented in a proforma and is summarized in Table 1 and 556 
Supplemental File 1. Blood from study participants was screened for Mtb infection by 557 
the standard QuantiFERON TB Gold In-tube test (Qiagen, Germany) performed at 558 
the blood collection centre in Madanapalle and were classified as either interferon 559 
gamma release assay (IGRA) positive or negative (86). IGRA+ subjects were enrolled 560 
only if they had no known TB disease and had not received preventive/curative 561 
therapy for TB in the past. Two hundred subjects were enrolled and then divided into 562 
four clinical groups based on their IGRA result and randomization to receive BCG 563 
(Figure 1A).   564 
Vaccination 565 
BCG vaccine (TUBERVAC, Russian BCG strain manufactured at Serum Institute of 566 
India, Pune) used widely in the Indian national immunization program was 567 
administered intradermally at day 0 at an adult dose of 2–8 x 105 CFU in participants 568 
from group 1 (IGRA+, N=28) and group 2 (IGRA-, N=30). Group 3 (IGRA+ N=24) and 569 
Group 4 (IGRA- N=23) were not BCG revaccinated and served as controls for 570 
Groups 1 and 2 respectively. As greater than 90% of the volunteers recruited were 571 
nursing students, Hepatitis B vaccination (HBV) was given to fulfill their immunization 572 
requirements as health care workers as they are at high risk for HBV; additionally, 573 
this vaccination enhanced compliance to our longitudinal BCG revaccination study 574 
protocol. All participants (irrespective of whether they received BCG or not) therefore 575 
received HBV vaccine at 4 (T2), 10 (T4) and 30 weeks post-BCG vaccination. Blood 576 
was collected from participants at days 0 (T0) and 3, and at weeks 4 (T2), 5 (T3), 10 577 
(T4) and 34 (T5) post-BCG vaccination (Figure 1, A and B). Some vaccinees, after 578 
BCG vaccination, reported minor side effects which included itching/rash/pain at the 579 
site of vaccination, mild fever, cough and headache (Supplemental File 1). No 580 
serious side effects were reported and none of the participants become active TB+ 581 
during the entire duration of study. 582 
Antigen and antibody reagents 583 
Peptide pools that spanned the amino acid sequence of mycobacterial proteins 584 
Ag85A, TB10.4 and HBV surface antigen were constructed. Each peptide was 15 585 
amino acids and overlapped by 12 amino acids with the next sequential peptide 586 
(BIoSynthesis) and was 1 g/ml as previously described (87). Four DosR regulon-587 
encoded latency antigens (Rv1733c, Rv1737c, Rv2029 and Rv2628) were 588 
synthesized as recombinant proteins at the Department of Infectious Diseases, 589 
Leiden University Medical Center, The Netherlands. BCG Vaccine (TUBERVAC) was 590 
reconstituted in RPMI 1640 (final concentration 1.2-33.0 x 106 CFU/ml blood). All 591 
intracellular cytokine staining (ICS) assay stimulations were performed in the 592 
presence of anti-CD28/CD49d co-stimulatory antibodies (at 1 g/ml, BD 593 
Biosciences). Fluorochrome conjugated monoclonal antibodies to cell surface and 594 
intracellular markers used in flow cytometry assays are listed in Supplemental Table 595 
1, A and B. Antibodies were sourced from BD Biosciences, BioLegend and 596 
eBioscience (Supplemental Table 1, A and B). 597 
Peripheral blood mononuclear cell isolation: Anticoagulated blood (16 ml) was 598 
collected in ACD tubes (BD, Franklin Lakes NJ, USA) and peripheral blood 599 
mononuclear cells (PBMCs) were isolated using ACCUSPIN (Sigma-Aldrich) tubes 600 
by density centrifugation following manufacturer's instructions. Blood was diluted two-601 
fold with PBS (Gibco by Life Technologies, Washington, DC, USA) + 2% FBS 602 
(Gibco), pipetted into ACCUSPIN tubes pre-filled with Histopaque 1077 and 603 
centrifuged at 1000g for 15 minutes at room temperature without deceleration. 604 
PBMCs from the buffy coat were washed twice with PBS + 2% FBS, then 605 
resuspended at 5 x 106 cells/mL in cryopreservation medium (90% FBS and 10% 606 
DMSO) and incubated overnight at -80°C (in Mr. Frosty™ freezing container; 607 
Nalgene, USA) and were stored in liquid nitrogen until further analyses.  608 
Intracellular cytokine staining (ICS) assay and multiparameter flow cytometry 609 
Whole blood: Heparinized whole blood was collected from participants and 610 
processed within 30-45 min of phlebotomy, as previously described (88). Briefly, 400 611 
l of blood was pipetted into Sarstedt tubes and stimulated with peptide pools (1 612 
g/ml per peptide) or with BCG (2.4 – 60 x 104 CFU/ml)  together with anti-613 
CD28/CD49d costimulatory mAbs at 0.5 g/ml. Phytohemagglutinin (PHA) (Remel, 614 
Thermo Fisher Scientific, UK) was used as a positive mitogen control and culture 615 
medium with anti-CD28/CD49d was used as unstimulated negative control. Blood 616 
was incubated at 37˚C for a total of 12 h, and Brefeldin A (Sigma-Aldrich) at a 617 
concentration of 10 g/ml was added in the final 5 h of stimulation. After stimulation, 618 
blood was treated with 2 M EDTA (Sigma), RBCs were lysed with 4.5 ml 1X FACS 619 
Lysing solution (BD), and fixed cells were transferred to liquid nitrogen in freezing 620 
medium containing 10% DMSO, 40% FCS, and 50% RPMI 1640. For staining, 621 
cryopreserved whole-blood samples were thawed in a water bath at 37°C for 2 min. 622 
Thawed cells were transferred to labelled tubes containing 2 mL of PBS and were 623 
centrifuged at 2000 rpm for 5 min. Cells were then stained with a 50 l cocktail 624 
containing cell surface antibodies for 30 min at room temperature (RT) in the dark. 625 
Next, cells were washed with PBS, permeabilized with 200 l 1X Perm/Wash solution 626 
(BD Biosciences) and incubated at RT for 20 min. Pelleted cells were immediately 627 
stained with a 50 l cocktail containing antibodies against intracellular markers for 30 628 
min at RT. Cells were washed and resuspended in 100 l of 1% paraformaldehyde 629 
(Electron Microscopy Sciences, USA) for flow cytometry analysis. 630 
PBMC: ICS assay with cryopreserved, antigen-stimulated PBMCs was performed as 631 
previously described (89). Cryopreserved PBMC samples were rapidly thawed in a 632 
37°C water bath, transferred to 15 ml tubes containing ~ 3 ml PBS and centrifuged at 633 
2000 rpm for 5 min at RT. One million cells resuspended in 200 µL culture medium 634 
[RPMI-1640 (GIBCO, Invitrogen) supplemented with 10% FCS (GIBCO), 100 U/ml 635 
penicillin and 100 µg/ml streptomycin, (Sigma)] were seeded per well in 96-well 636 
round-bottom plates (Costar) and stimulated with either Ag85A peptide pools (1 637 
µg/ml) or recombinant latency proteins (10 µg/ml) or BCG (2.4 – 60 x 104 CFU/ml) or 638 
PHA (1 µg/ml) at 37°C and 5% CO2. After 4 h of stimulation, brefeldin A (10 µg/ml) 639 
was added. On the next day, PBMC were washed after incubation with EDTA and 640 
first stained with 5 μl Live/Dead Aqua (Invitrogen) followed by a 50 μl cell surface 641 
staining cocktail for 30 min at RT in the dark. Cells were then fixed for 20 min with 642 
100 μl 1X FACS lysis buffer and permeabilized with 200 μl 1X BD Perm/Wash buffer 643 
for 20 min. PBMCs were washed and incubated for 30 min at RT in the dark with a 644 
50 μl intracellular staining cocktail. Finally, cells were washed with 150 μl Perm/Wash 645 
buffer and resuspended in ~100μl of 1% paraformaldehyde for flow cytometry 646 
analysis. 647 
 648 
Flow cytometry analysis: Samples were acquired on BD FACSAriaTM Fusion flow 649 
cytometer and BD FACSDivaTM version 8.0.1 software (BD Biosciences). Cytometer 650 
Setting and Tracking (CST) beads (BD Biosciences) were acquired before each 651 
experiment to ensure consistency across all experiments. Stained samples were 652 
acquired with a standard stopping gate set at 1 x 105 CD3+ lymphocytes. Unstained 653 
cells and single-stained beads (eBioscience) were used for calculating the 654 
compensation matrix. Data was analyzed and Boolean cytokine combinations were 655 
generated using FlowJo version 9.9.4 software (Treestar, Ashland, OR). Background 656 
subtractions were performed in Pestle version 1.8.  657 
 658 
COMPASS application of flow cytometry data: Cell counts were analyzed using 659 
the COMbinatorial Polyfunctionality Analysis of Antigen-Specific T-cell Subsets 660 
(COMPASS) algorithm as described (66). Briefly, COMPASS is a statistical model 661 
developed for high-dimensional flow cytometry data analysis that can detect antigen-662 
specific changes across all observable functional T-cell subsets, without the need to 663 
limit the analysis to very specific subsets based on expected biological significance.  664 
COMPASS was applied to the three antigens in two (CD4+ and CD8+) T-cell subsets 665 
leading to 20 analyses. Each analysis was unbiased and considered all of the 31 666 
possible cytokine functions (defined as Boolean combination). To evaluate 667 
differences in polyfunctionality between groups, a linear model estimating the group 668 
wise mean polyfunctionality scores was fit to each antigen and the difference 669 
between IGRA+ and other groups was tested (Wald test, null: 𝛽 −  𝛽 =  0, 670 
two-sided test). Resulting p-values were adjusted for multiple testing (across all 60 671 
tests and models) to control the FDR (false discovery rate) using the method of 672 
Benjamini & Hochberg (90). Significant differences were designated at the 5% FDR 673 
level. Magnitudes of T-cell responses were calculated independent of COMPASS as 674 
the maximum of zero or the proportion of gated events in the stimulated condition 675 
minus the proportion of gated events in the unstimulated condition. 676 
 677 
Hepatitis B ELISA: Antibodies to hepatitis B surface antigen were measured in 678 
plasma at 1:2 dilution using the anti-HepB surface antigen ELISA kit from XpressBio 679 
Life Science Products (catalogue number WB2896, Frederick, MD). All study 680 
participants received three doses of HBV (Figure 1). However, we did not notice any 681 
benefits of BCG vaccination on Hep B responses in our study as all subjects across 682 
all 4 groups in our study had comparable peak Hep B antibody titers at T5 (week 35) 683 
post third Hep B vaccination with no significant differences of the peak response over 684 
time points tested (Supplemental Figure 8). 685 
 686 
Statistical Analysis: All antigen-stimulated wells were adjusted for nonspecific 687 
responses by background subtraction (media alone). Statistical analyses were 688 
performed and graphs were created using GraphPad Prism software version 6.0.7 689 
(GraphPad, La Jolla, CA). Paired longitudinal comparisons within the same group 690 
were done using the two-sided Wilcoxon matched pairs signed rank test. 691 
Comparisons across two treatment groups were done using unpaired Mann–Whitney 692 
U test. One-way analysis of variance (ANOVA) test, followed by Bonferroni post-hoc 693 
tests for multiple comparisons was used to compare three cytokines between two 694 
groups. Differences were considered statistically significant for p-value <0.05. Box-695 
and-whisker plot depicts the interquartile range with median bars and with whiskers 696 
depicting minimum and maximum values. Scatter plots depict median values with 697 
range. In Figures 3C, 3G, 4C and 4G mean ± SD was plotted.  698 
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Figure 1: Overall study design. (A) CONSORT flow diagram of participant 1025 
recruitment and enrolment. (B) A diagrammatic representation of study design 1026 
including schedule of vaccination and blood draw. Group 1 and Group 2 received 1027 
BCG at day 0 (T0) and then three doses of HBV vaccine at weeks 4 (T2), 10 and 30 1028 
(T4). Group 3 and Group 4 did not receive BCG vaccine but three doses of HBV. 1029 
Immunization time points are shown by blue arrows and the six blood sampling time 1030 
points (T0-T5) are indicated by red arrows for all groups.  1031 
 1032 
Figure 2: Baseline Mtb antigen-specific T-cell responses in whole blood of 1033 
IGRA+ vs. IGRA- subjects. Scatter plots of Ag85A, TB10.4 and BCG reactive IFN-γ 1034 
and/or IL-2 expressing CD4+ (upper panels) and CD8+ (lower panels) T-cells in whole 1035 
blood are shown after background subtraction at baseline in IGRA+ vs. IGRA- 1036 
subjects. Number of subjects in each group range from 38 to 42. Significant 1037 
differences between groups were determined using the Mann–Whitney U test (P 1038 
values < 0.05 are shown). 1039 
 1040 
Figure 3: Longitudinal analysis reveals that BCG revaccination significantly 1041 
enhances Ag85A- and BCG-specific IFN-γ and/or IL-2 CD4 T-cell responses in 1042 
whole blood. Left hand panel shows ICS data for Ag85A and right-hand panel for 1043 
BCG following in vitro stimulation of whole blood from BCG revaccinated and control 1044 
subjects. Representative flow cytometry plots show IFN-γ and/or IL-2 cytokine 1045 
positive CD4+ T-cells after in vitro stimulation with either Ag85A (A) or BCG (E) at T0, 1046 
T2 (A) and T5 (E). Total frequencies of Ag85A (B) and BCG-specific (F) IFN-γ and/or 1047 
IL-2 cytokine-positive CD4+ T-cells in all participants are shown after background 1048 
subtraction. Line graphs show changes in frequencies of specific CD4+ T-cells over 1049 
time in BCG revaccinated [Group 1 (IGRA+, red, N = 19) and Group 2 (IGRA-, blue, N 1050 
= 18)] subjects and unvaccinated controls [Group 3 (IGRA+, black, N = 18) and 1051 
Group 4 (IGRA-, brown, N = 18)]. P values for longitudinal samples were calculated 1052 
by comparing each time point to baseline using the Freidman test and corrected for 1053 
multiple comparisons using Dunn’s test. Further, significant differences were 1054 
determined using the Wilcoxon paired t-test pre and post vaccination. Bonferroni 1055 
adjusted P value threshold of 0.02 was considered statistically significant. Median 1056 
frequencies of Ag85A (C) and BCG (G) specific IFN-γ and/or IL-2 cytokine positive 1057 
CD4+ T-cells over time were compared between unvaccinated and revaccinated 1058 
IGRA+ and IGRA- subjects (Group 1 vs Group 3 and Group 2 vs Group 4). Mann-1059 
Whitney U test was used to determine significant differences between groups. P < 1060 
0.05 was considered significant. Analysis of CD45RA and CD27 expression was 1061 
used to determine percentage distribution of naïve (CD45RA+CD27+,), central 1062 
memory (CM, CD45RA-CD27+), effector memory (EM, CD45RA-CD27-) and 1063 
terminally-differentiated T effector memory cells (TD, CD45RA+CD27-) Ag85A (D) 1064 
and BCG (H)-specific IFN-γ and/or IL-2 CD4+ T-cells in BCG-revaccinated [Group 1 1065 
(IGRA+) and Group 2 (IGRA-)] subjects. Wilcoxon paired t-test was used to determine 1066 
significant differences pre and post vaccination. P < 0.05 was considered significant.  1067 
 1068 
Figure 4: Longitudinal analysis reveals that BCG revaccination significantly 1069 
enhances Ag85A- and BCG-specific IFN-γ and/or IL-2 CD8 T-cell in whole 1070 
blood. Left hand panel shows ICS data for Ag85A and right-hand panel for BCG 1071 
following in vitro stimulation of whole blood from BCG revaccinated and control 1072 
subjects. Representative flow cytometry plots show IFN-γ and/or IL-2 cytokine 1073 
positive CD8+ T-cells after in vitro stimulation with either Ag85A (A) or BCG (E) at T0, 1074 
T2 (A) and T5 (E). Total frequencies of Ag85A (B) and BCG-specific (F) IFN-γ and/or 1075 
IL-2 cytokine positive CD8+ T-cells in all participants are shown after background 1076 
subtraction. Line graphs show changes in frequencies of specific CD8+ T-cells over 1077 
time in BCG revaccinated [Group 1 (IGRA+, red, N = 19) and Group 2 (IGRA-, blue, N 1078 
= 18)] subjects and unvaccinated controls [Group 3 (IGRA+, black, N = 18) and 1079 
Group 4 (IGRA-, brown, N = 18)]. P values for longitudinal samples were calculated 1080 
by comparing each time point to baseline using the Freidman test and corrected for 1081 
multiple comparisons using Dunn’s test. Further, significant differences were 1082 
determined using the Wilcoxon paired t-test pre and post vaccination. Bonferroni 1083 
adjusted P value threshold of 0.02 was considered statistically significant. Median 1084 
frequencies of Ag85A (C) and BCG (G) specific IFN-γ and/or IL-2 cytokine-positive 1085 
CD8+ T-cells over time were compared between unvaccinated and revaccinated 1086 
IGRA+ and IGRA- subjects (Group 1 ‘vs’ Group 3 and Group 2 ‘vs’ Group 4). Mann-1087 
Whitney U test was used to determine significant differences between groups. P < 1088 
0.05 was considered significant. Analysis of CD45RA and CD27 expression was 1089 
used to determine percentage distribution of naïve (CD45RA+CD27+,), central 1090 
memory (CM, CD45RA-CD27+), effector memory (EM, CD45RA-CD27-) and 1091 
terminally-differentiated T effector memory cells (TD, CD45RA+CD27-) Ag85A (D) 1092 
and BCG (H)-specific IFN-γ and/or IL-2 CD8+ T-cells in BCG-revaccinated [Group 1 1093 
(IGRA+) and Group 2 (IGRA-)] subjects. Wilcoxon paired t-test was used to determine 1094 
significant differences pre and post vaccination. P < 0.05 was considered significant.  1095 
 1096 
Figure 5: Comparative analysis of whole blood and PBMC ICS assay reveals 1097 
similar pattern of increase in CD4+ T-cell responses post BCG revaccination. 1098 
(A) IFN-γ and/or IL-2 frequencies in response to Ag85A (T2) and BCG (T5) 1099 
stimulation were compared in matched whole blood and PBMC samples from IGRA+ 1100 
Group 1 subjects. Spearman’s correlation coefficient (r) and significance values (P) 1101 
are indicated. (B) Box and whiskers plots show changes in IFN-γ and/or IL-2 1102 
frequencies of CD4+ T-cells over time in BCG revaccinated IGRA+ (Group 1) to in 1103 
vitro Ag85A (left panel) or BCG (right panel) re-stimulation in whole blood (N=19) and 1104 
PBMC (N=10). Significant differences pre and post-vaccination were determined 1105 
using the Wilcoxon paired t-test. P < 0.05 was considered significant.  1106 
 1107 
Figure 6: COMPASS analysis reveals enhanced polyfunctionality scores in 1108 
CD4+ and CD8+ T-cell responses in whole blood to Ag85A and BCG stimulation 1109 
following BCG revaccination. (Compass polyfunctionality scores (PFS) for CD4 1110 
and CD8 T-cell subsets were determined for each group and for each antigen 1111 
stimulation at T0 (baseline), T2 (4 weeks), T4 (10 weeks) and T5 (34 weeks) post-1112 
BCG revaccination. Pairwise differences between time points were based on a group 1113 
wise linear model fit to the PFS (null: β ̂_(T2/T5)-β ̂_T0=0 two-sided test). 1114 
Polyfunctionality scores were calculated for (Group 1 N=21, Group 2 N=20, Group 3 1115 
N=18, Group 4 N=18). Statistical analysis was performed using paired Wilcoxon test 1116 
compared to baseline. 1117 
  1118 
Figure 7: COMPASS heat maps showing different polyfunctional CD4+ and 1119 
CD8+ T-cell subsets post BCG vaccination. Stacked COMPASS heat maps 1120 
displaying CD4+ (upper panel) and CD8+ (lower panel) whole blood T-cell responses 1121 
to Ag85A (left panel) and BCG (right panel) in BCG re-vaccinees [Group 1 (IGRA+, 1122 
orange) and Group 2 (IGRA-, bright green)] versus unvaccinated controls [Group 3 1123 
(IGRA+, light green) and Group 4 (IGRA-,blue)]. In the heat map, columns correspond 1124 
to the different disjoinT-cell subsets in which responses were detected and are color-1125 
coded in the x-axis legend by the cytokines they express (white = “off”, shaded = 1126 
“on”, grouped by colour = “degree of functionality”), and are displayed in order of 1127 
increasing functionality from left to right (sky blue to peach). For example, the first 1128 
column represents CD4+ T-cells that produce IFN-γ but none of the other functions. 1129 
Rows represent study subjects (Group 1 N=21, Group 2 N=20, Group 3 N=18, Group 1130 
4 N=18), which are ordered by the group they belong to and the time point [0 1131 
(turquoise) and 4 (pink) weeks for Ag85A and 0 (turquoise) and 34 (pink) weeks for 1132 
BCG] as shown in the legend at the right. Each cell of the heatmap shows the 1133 
probability estimated by COMPASS that the observed response is antigen-specific in 1134 
the corresponding subject (row) and cell subset (column), where the probability is 1135 
color-coded from white (zero) to purple (one). A probability of 0 indicates certainty 1136 
that the observed response is background, while a probability of 1 indicates certainty 1137 
that the observed response is antigen-specific. Horizontal lines were added to 1138 
separate the time points and red boxes were inserted to highlight the subsets of 1139 
interest. 1140 
 1141 
Figure 8: Polyfunctional CD4+ T-cell responses induced upon BCG 1142 
revaccination are comparable in whole blood and PBMC of BCG revaccinated 1143 
IGRA+ subjects. (A) Polyfunctionality scores at T5 were calculated for CD4+ T-cells 1144 
post re-stimulation of whole blood (Group 1 N=21, Group 2 N=20, Group 3 N=18, 1145 
Group 4 N=18) with Ag85A or BCG taking into account T-cells positive for IL-2, IFN-1146 
γ, TNF-α, IL-17A and MIP-1β. (B) Similarly, polyfunctionality scores at T5 were 1147 
calculated for CD4+ T-cells post re-stimulation of PBMCs (N=10) with Ag85A, BCG or 1148 
LTAg taking into account T-cells positive for IFN-γ, IL-2, TNF, IL-17A, IL-17F, IL-22, 1149 
IL-10 and MIP-1. Box and whisker plots show comparison of COMPASS 1150 
polyfunctionality scores (PFS) between revaccinated subjects (Group 1 & 2) and 1151 
unvaccinated subjects (Group 3 & 4) in both whole blood and PBMCs. Statistical 1152 
significance of differences between groups was determined by Mann-Whitney U test. 1153 
P < 0.05 was considered significant. 1154 
Figure 9: BCG revaccination significantly induces Mtb-specific cytokines in 1155 
PBMC. Representative flow cytometry plots (upper panel) show total IFN-γ, IL-17A, 1156 
IL-17F, IL-22 and IL-10 cytokine positive CD4+ T-cells after in vitro stimulation with 1157 
BCG at T5 in Group 1 vs Group 3 subject. The flow cytometry plots for the same 1158 
donors from Group 1 and 3 for BCG stimulation are shown again in Supplemental 1159 
Figure 4 and 5. Mtb-specific T-cell responses in PBMCs from BCG revaccinated 1160 
IGRA+ and IGRA- subjects (Group 1 & 2, N=10) were compared with unvaccinated 1161 
control IGRA+ and IGRA- subjects (Group 3 & 4, N=10) in a standard ICS assay 1162 
(lower panel). PBMCs were stimulated with Ag85A or BCG or a pool of LTAg 1163 
(Rv1733c, Rv1737c, Rv2029 & Rv2628). CD3+CD4+ T-cells were analysed for 1164 
intracellular expression of indicated cytokines. Scatter plots show median (range) 1165 
percentages of total IFN-γ, IL-17A, IL-17F, IL-22 and IL-10-positive CD4+ T-cells. 1166 
Unadjusted p-values were calculated with the Mann-Whitney U-test, comparing 1167 
frequencies of cytokine-positive cells between the two groups. To correct for multiple 1168 
testing (Bonferroni method), P-values below 0.025 were considered statistically 1169 
significant.  1170 
 1171 
Figure 10: BCG revaccination significantly induces Mtb-specific regulatory IL-1172 
10+Th17 responses. CD4+ T-cell subsets expressing IL-17A, IL-17F, or IL-22 (Th17) 1173 
either in combination with IFN-γ or IL-10 from BCG revaccinated IGRA+ and IGRA- 1174 
subjects (Group 1 & 2, N=10) were compared with unvaccinated control IGRA+ and 1175 
IGRA- subjects (Group 3 & 4, N=10) at T5 post-BCG vaccination to Ag85A, BCG and 1176 
LTAg stimulation. For this analysis, we calculated cytokine-positive cells based on 1177 
the gating shown in Supplemental Figure 6. Statistical analysis was performed using 1178 
a one-way ANOVA with Bonferroni post hoc test defining differences as significant 1179 
(*p < 0.05). 1180 
Figure 11: BCG revaccination induces innate effector response in whole blood. 1181 
Line graphs show the frequencies of IFN-γ-expressing γδ T, NKT, CD56br NK and 1182 
CD56dim NK cells in BCG revaccinated IGRA+ and IGRA- subjects (Group 1, N=20 & 1183 
Group 2, N=18) versus unvaccinated control IGRA+ and IGRA- subjects (Group 3, 1184 
N=19 & Group 4, N=18) to Ag85A and BCG stimulation at baseline and at T2 and T5 1185 
post-BCG revaccination respectively. Significance between longitudinal samples in a 1186 
group was calculated using Wilcoxon matched pairs test. P<0.05 was considered 1187 
significant. 1188 
 1189 
Table 1: Clinical Characteristics of Study Recruits. Median age for all the clinical 1190 
group is 20 or close to 20 except group 3 is 19. Male-female ratio in each clinical 1191 
group is close to 1 except group 4. There was no significance difference found 1192 
between male-female IGRA level (QuantiFERON-TB Gold) except group 1 (P=0.01), 1193 
however there was no significance difference between male-female background 1194 













IGRA level median 
(Range) 
1 21 20 (19-28) 42.86 57.14 3.6 (0.46-10) 
2 23 20 (18-23) 39.1 60.87 0.04 (0.01-0.3) 
3 18 19 (18-23) 61.11 38.89 2 (0.58-10) 
4 18 19.5 (18-23) 22.22 77.78 0.1 (0-0.3) 
 1197 
SUPPLEMENTAL FIGURE LEGENDS 1198 
Supplemental Figure 1: Flow cytometry gating strategy for T-cell analysis in 1199 
whole blood. Schematic representation of flow cytometry plots showing sequential 1200 
gating strategy of whole blood cells for analysis of CD4+ and CD8+ T-cells. All gates 1201 
for non-functional markers were defined using fluorescence minus one (FMO) 1202 
controls; gates for functional markers were defined using the unstimulated samples. 1203 
Initial gating was done on FSC-H and FSC-A to discriminate singlets, followed by the 1204 
exclusion of CD14+ monocytes. Lymphocytes were gated using FSC-A and SSC-A. 1205 
Within the lymphocyte gate, CD3+ cells were identified, followed by CD4+ and CD8+ 1206 
T-cells. CD27 and CD45RA expression within CD4+ and CD8+ T-cell subsets was 1207 
used to define memory phenotypes (naïve, CM, EM and TD). To define functional 1208 
markers for CD4+ and CD8+ T-cells, a gate was applied for each cytokine, not taking 1209 
into account the co-expression of other markers. Boolean gates were then created 1210 
based on these gates to identify cells expressing different combinations of markers.  1211 
Supplemental Figure 2: TB10.4-specific CD4+ and CD8+ T-cell responses in 1212 
whole blood before and after BCG revaccination. Line graphs show changes in 1213 
TB10.4 specific IFN-γ and/or IL-2 frequencies of CD4+ and CD8+ T-cells over time in 1214 
BCG vaccinated IGRA+ (Group 1, N=19) and IGRA- (Group 2, N=18) subjects versus 1215 
unvaccinated control IGRA+ (Group 3, N=18) and IGRA- (Group 4, N=18) subjects. 1216 
Supplemental Figure 3: Flow cytometry gating strategy for T-cell analysis in 1217 
PBMC. Schematic representation of flow cytometry plots showing sequential gating 1218 
strategy of PBMCs for analysis of CD4+ and CD8+ T-cells. All gates for non-functional 1219 
markers were defined using fluorescence minus one (FMO) controls; gates for 1220 
functional markers were defined using the unstimulated samples. Initial gating was 1221 
done on FSC-H and FSC-A to discriminate singlets, followed by the exclusion of 1222 
dead cells by AVID stain. Lymphocytes were gated using FSC-A and SSC-A. Within 1223 
the lymphocyte gate, CD3+ cells were identified, followed by CD4+ and CD8+ T-cells. 1224 
To define functional markers for CD4+ T-cells, a gate was applied for each cytokine, 1225 
not taking into account the co-expression of other markers. Boolean gates were then 1226 
created based on these gates to identify cells expressing different combinations of 1227 
markers. 1228 
Supplemental Figure 4: CD4+ T-cell cytokine responses in PBMC to BCG 1229 
stimulation. Representative flow cytometry plots (from same donors as shown in 1230 
Figure 9) show total IFN-γ, IL-2, IL-17A, IL-17F, IL-22 and IL-10 cytokine positive 1231 
CD4+ T-cells in unstimulated control and after in vitro stimulation with BCG at T5 in 1232 
Group 1 versus Group 3 subjects. 1233 
Supplemental Figure 5: Th17 subsets in PBMC to Mtb antigens and BCG 1234 
stimulation. Representative flow cytometry plots (from same donors as shown in 1235 
Figure 9) show CD4+Th17 subsets expressing either IFN-γ or IL-10 with IL-17F with 1236 
or without in vitro stimulation of PBMC with Ag85A, BCG, LTAg at T5 in a Group 1 1237 
subject. The quadrant gates for the cytokines were positioned closer to the negative 1238 
cells for these analyses to examine the Th17 double-positive cells. Since those cells 1239 
are rare and the MFI of the cytokines on those cells is low, the lower position of the 1240 
quadrant was necessary to include those cells.  1241 
Supplemental Figure 6: Th17 subsets in PBMC to BCG stimulation. 1242 
Representative flow cytometry plots show CD4+Th17 subsets expressing either IFN-γ 1243 
or IL-10 with IL-17F with or without in vitro stimulation of PBMC with BCG at T5 in 1244 
two additional Group 1 subjects.  1245 
Supplemental Figure 7: Gating Strategy for Innate Cells. A representative 1246 
sequential gating strategy for NKT, CD56br NK, CD56dim NK and  T-cells in whole 1247 
blood is shown. Frequencies of IFN-γ expressing cells were studied in all 1248 
populations. 1249 
Supplemental Figure 8: BCG revaccination did not impact Hep B antibody titer 1250 
in study participants. Hep B antibody titer was measured in plasma of study 1251 
participants at T0, T1, T2, T4 and T5. Antibody titer was measured by standard 1252 
ELISA and concentration was expressed as IU/ml. N for Group 1 = 16, Group 2=10, 1253 
Group 3=16 and Group 4=10. P values for longitudinal samples were calculated by 1254 
comparing each time point to baseline using the Freidman test and corrected for 1255 
multiple comparisons using Dunn’s test. 1256 
Supplemental Table 1: Panel of antibodies used for cell surface and intracellular 1257 
markers for (A) whole blood and (B) PBMC ICS assays.  1258 
Supplemental File 1: Clinical details of study participants who were included in final 1259 
data analysis. 1260 
 1261 
 1262 
Figure 1: Overall study design. (A) CONSORT flow diagram of participant recruitment and enrolment. (B) A diagrammatic representation of study design including
schedule of vaccination and blood draw. Group 1 and Group 2 received BCG at day 0 (T0) and then three doses of HBV vaccine at weeks 4 (T2), 10 and 30 (T4). Group 3
and Group 4 did not receive BCG vaccine but three doses of HBV. Immunization time points are shown by blue arrows and the six blood sampling time points (T0-T5) are
indicated by red arrows for all groups.
Figure 2: Baseline Mtb antigen-specific T-cell responses in whole blood of IGRA+ vs. IGRA- subjects. Scatter plots of Ag85A,
TB10.4 and BCG reactive IFN-γ and/or IL-2 expressing CD4+ (upper panels) and CD8+ (lower panels) T-cells in whole blood are shown
after background subtraction at baseline in IGRA+ vs. IGRA- subjects. Number of subjects in each group range from 38 to 42. Significant
differences between groups were determined using the Mann–Whitney U test (P values < 0.05 are shown).
Figure 3: Longitudinal analysis reveals that BCG revaccination
significantly enhances Ag85A- and BCG-specific IFN-γ and/or IL-2
CD4 T-cell responses in whole blood. Left hand panel shows ICS data
for Ag85A and right-hand panel for BCG following in vitro stimulation of
whole blood from BCG revaccinated and control subjects. Representative
flow cytometry plots show IFN-γ and/or IL-2 cytokine positive CD4+ T-cells
after in vitro stimulation with either Ag85A (A) or BCG (E) at T0, T2 (A) and
T5 (E). Total frequencies of Ag85A (B) and BCG-specific (F) IFN-γ and/or
IL-2 cytokine-positive CD4+ T-cells in all participants are shown after
background subtraction. Line graphs show changes in frequencies of
specific CD4+ T-cells over time in BCG revaccinated [Group 1 (IGRA+, red,
N = 19) and Group 2 (IGRA-, blue, N = 18)] subjects and unvaccinated
controls [Group 3 (IGRA+, black, N = 18) and Group 4 (IGRA-, brown, N =
18)]. P values for longitudinal samples were calculated by comparing each
time point to baseline using the Freidman test and corrected for multiple
comparisons using Dunn’s test. Further, significant differences were
determined using the Wilcoxon paired t-test pre and post vaccination.
Bonferroni adjusted P value threshold of 0.02 was considered statistically
significant. Median frequencies of Ag85A (C) and BCG (G) specific IFN-γ
and/or IL-2 cytokine positive CD4+ T-cells over time were compared
between unvaccinated and revaccinated IGRA+ and IGRA- subjects (Group
1 vs Group 3 and Group 2 vs Group 4). Mann-Whitney U test was used to
determine significant differences between groups. P < 0.05 was considered
significant. Analysis of CD45RA and CD27 expression was used to
determine percentage distribution of naïve (CD45RA+CD27+,), central
memory (CM, CD45RA-CD27+), effector memory (EM, CD45RA-CD27-) and
terminally-differentiated T effector memory cells (TD, CD45RA+CD27-)
Ag85A (D) and BCG (H)-specific IFN-γ and/or IL-2 CD4+ T-cells in BCG-
revaccinated [Group 1 (IGRA+) and Group 2 (IGRA-)] subjects. Wilcoxon
paired t-test was used to determine significant differences pre and post
vaccination. P < 0.05 was considered significant.
Figure 4: Longitudinal analysis reveals that BCG revaccination significantly
enhances Ag85A- and BCG-specific IFN-γ and/or IL-2 CD8 T-cell in whole
blood. Left hand panel shows ICS data for Ag85A and right-hand panel for BCG
following in vitro stimulation of whole blood from BCG revaccinated and control
subjects. Representative flow cytometry plots show IFN-γ and/or IL-2 cytokine
positive CD8+ T-cells after in vitro stimulation with either Ag85A (A) or BCG (E) at
T0, T2 (A) and T5 (E). Total frequencies of Ag85A (B) and BCG-specific (F) IFN-γ
and/or IL-2 cytokine positive CD8+ T-cells in all participants are shown after
background subtraction. Line graphs show changes in frequencies of specific
CD8+ T-cells over time in BCG revaccinated [Group 1 (IGRA+, red, N = 19) and
Group 2 (IGRA-, blue, N = 18)] subjects and unvaccinated controls [Group 3
(IGRA+, black, N = 18) and Group 4 (IGRA-, brown, N = 18)]. P values for
longitudinal samples were calculated by comparing each time point to baseline
using the Freidman test and corrected for multiple comparisons using Dunn’s
test. Further, significant differences were determined using the Wilcoxon paired t-
test pre and post vaccination. Bonferroni adjusted P value threshold of 0.02 was
considered statistically significant. Median frequencies of Ag85A (C) and BCG (G)
specific IFN-γ and/or IL-2 cytokine-positive CD8+ T-cells over time were
compared between unvaccinated and revaccinated IGRA+ and IGRA- subjects
(Group 1 ‘vs’ Group 3 and Group 2 ‘vs’ Group 4). Mann-Whitney U test was used
to determine significant differences between groups. P < 0.05 was considered
significant. Analysis of CD45RA and CD27 expression was used to determine
percentage distribution of naïve (CD45RA+CD27+,), central memory (CM,
CD45RA-CD27+), effector memory (EM, CD45RA-CD27-) and terminally-
differentiated T effector memory cells (TD, CD45RA+CD27-) Ag85A (D) and BCG
(H)-specific IFN-γ and/or IL-2 CD8+ T-cells in BCG-revaccinated [Group 1
(IGRA+) and Group 2 (IGRA-)] subjects. Wilcoxon paired t-test was used to
determine significant differences pre and post vaccination. P < 0.05 was
considered significant.
Figure 5: Comparative analysis of whole blood and PBMC ICS assay reveals similar pattern of increase in CD4+ T-cell responses post BCG revaccination. (A)
IFN-γ and/or IL-2 frequencies in response to Ag85A (T2) and BCG (T5) stimulation were compared in matched whole blood and PBMC samples from IGRA+ Group 1
subjects. Spearman’s correlation coefficient (r) and significance values (P) are indicated. (B) Box and whiskers plots show changes in IFN-γ and/or IL-2 frequencies of CD4+
T-cells over time in BCG revaccinated IGRA+ (Group 1) to in vitro Ag85A (left panel) or BCG (right panel) re-stimulation in whole blood (N=19) and PBMC (N=10).
Significant differences pre and post-vaccination were determined using the Wilcoxon paired t-test. P < 0.05 was considered significant.
Figure 6: COMPASS analysis reveals enhanced polyfunctionality scores in CD4+ and CD8+ T-cell responses in whole blood to Ag85A and BCG 
stimulation following BCG revaccination. (Compass polyfunctionality scores (PFS) for CD4 and CD8 T-cell subsets were determined for each group and 
for each antigen stimulation at T0 (baseline), T2 (4 weeks), T4 (10 weeks) and T5 (34 weeks) post-BCG revaccination. Pairwise differences between time 
points were based on a group wise linear model fit to the PFS (null: β _̂(T2/T5)-β _̂T0=0 two-sided test). Polyfunctionality scores were calculated for (Group 1 
N=21, Group 2 N=20, Group 3 N=18, Group 4 N=18). Statistical analysis was performed using paired Wilcoxon test compared to baseline.
Figure 7: COMPASS heat maps showing different polyfunctional CD4+ and CD8+ T-cell subsets post BCG vaccination. Stacked COMPASS heat maps
displaying CD4+ (upper panel) and CD8+ (lower panel) whole blood T-cell responses to Ag85A (left panel) and BCG (right panel) in BCG re-vaccinees [Group 1
(IGRA+, orange) and Group 2 (IGRA-, bright green)] versus unvaccinated controls [Group 3 (IGRA+, light green) and Group 4 (IGRA-,blue)]. In the heat map, columns
correspond to the different T-cell subsets in which responses were detected and are color-coded in the x-axis legend by the cytokines they express (white = “off”,
shaded = “on”, grouped by colour = “degree of functionality”), and are displayed in order of increasing functionality from left to right (sky blue to peach). For example,
the first column represents CD4+ T-cells that produce IFN-γ but none of the other functions. Rows represent study subjects (Group 1 N=21, Group 2 N=20, Group 3
N=18, Group 4 N=18), which are ordered by the group they belong to and the time point [0 (turquoise) and 4 (pink) weeks for Ag85A and 0 (turquoise) and 34 (pink)
weeks for BCG] as shown in the legend at the right. Each cell of the heatmap shows the probability estimated by COMPASS that the observed response is antigen-
specific in the corresponding subject (row) and cell subset (column), where the probability is color-coded from white (zero) to purple (one). A probability of 0 indicates
certainty that the observed response is background, while a probability of 1 indicates certainty that the observed response is antigen-specific. Horizontal lines were
added to separate the time points and red boxes were inserted to highlight the subsets of interest.
Figure 8: Polyfunctional CD4+ T-cell responses induced upon BCG revaccination are comparable in whole blood and PBMC of BCG revaccinated IGRA+
subjects. (A) Polyfunctionality scores at T5 were calculated for CD4+ T-cells post re-stimulation of whole blood (Group 1 N=21, Group 2 N=20, Group 3 N=18, Group 4
N=18) with Ag85A or BCG taking into account T-cells positive for IL-2, IFN-γ, TNF-α, IL-17A and MIP-1β. (B) Similarly, polyfunctionality scores at T5 were calculated for
CD4+ T-cells post re-stimulation of PBMCs (N=10) with Ag85A, BCG or LTAg taking into account T-cells positive for IFN-γ, IL-2, TNFα, IL-17A, IL-17F, IL-22, IL-10 and
MIP-1β. Box and whisker plots show comparison of COMPASS polyfunctionality scores (PFS) between revaccinated subjects (Group 1 & 2) and unvaccinated subjects
(Group 3 & 4) in both whole blood and PBMCs. Statistical significance of differences between groups was determined by Mann-Whitney U test. P < 0.05 was considered
significant.
Figure 9: BCG revaccination significantly induces Mtb-specific cytokines in PBMC. Representative flow cytometry plots (upper panel) show total IFN-γ, IL-17A, IL-17F, IL-22
and IL-10 cytokine positive CD4+ T-cells after in vitro stimulation with BCG at T5 in Group 1 vs Group 3 subject. The flow cytometry plots for the same donors from Group 1 and 3
for BCG stimulation are shown again in Supplemental Figure 4 and 5. Mtb-specific T-cell responses in PBMCs from BCG revaccinated IGRA+ and IGRA- subjects (Group 1 & 2,
N=10) were compared with unvaccinated control IGRA+ and IGRA- subjects (Group 3 & 4, N=10) in a standard ICS assay (lower panel). PBMCs were stimulated with Ag85A or
BCG or a pool of LTAg (Rv1733c, Rv1737c, Rv2029 & Rv2628). CD3+CD4+ T-cells were analysed for intracellular expression of indicated cytokines. Scatter plots show median
(range) percentages of total IFN-γ, IL-17A, IL-17F, IL-22 and IL-10-positive CD4+ T-cells. Unadjusted p-values were calculated with the Mann-Whitney U-test, comparing
frequencies of cytokine-positive cells between the two groups. To correct for multiple testing (Bonferroni method), P-values below 0.025 were considered statistically significant.
Figure 10: BCG revaccination significantly induces Mtb-specific regulatory IL-10+Th17 responses. CD4+ T-cell subsets expressing IL-17A, IL-17F, or IL-22 (Th17)
either in combination with IFN-γ or IL-10 from BCG revaccinated IGRA+ and IGRA- subjects (Group 1 & 2, N=10) were compared with unvaccinated control IGRA+ and
IGRA- subjects (Group 3 & 4, N=10) at T5 post-BCG vaccination to Ag85A, BCG and LTAg stimulation. For this analysis, we calculated cytokine-positive cells based on
the gating shown in Supplemental Figure 6. Statistical analysis was performed using a one-way ANOVA with Bonferroni post hoc test defining differences as significant
(*p < 0.05).
Figure 11: BCG revaccination induces innate effector
response in whole blood. Line graphs show the frequencies of
IFN-γ-expressing γδ T, NKT, CD56br NK and CD56dim NK cells in
BCG revaccinated IGRA+ and IGRA- subjects (Group 1, N=20 &
Group 2, N=18) versus unvaccinated control IGRA+ and IGRA-
subjects (Group 3, N=19 & Group 4, N=18) to Ag85A and BCG
stimulation at baseline and at T2 and T5 post-BCG
revaccination respectively. Significance between longitudinal
samples in a group was calculated using Wilcoxon matched
pairs test. P<0.05 was considered significant.
